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Abstract
Background: We have previously shown that a panel of kallikrein markers - total prostate-specific antigen (PSA),
free PSA, intact PSA and human kallikrein-related peptidase 2 (hK2) - can predict the outcome of prostate biopsy in
men with elevated PSA. Here we investigate the properties of our panel in men subject to clinical work-up before
biopsy.
Methods: We applied a previously published predictive model based on the kallikrein panel to 262 men
undergoing prostate biopsy following an elevated PSA (≥ 3 ng/ml) and further clinical work-up during the
European Randomized Study of Prostate Cancer screening, France. The predictive accuracy of the model was
compared to a “base” model of PSA, age and digital rectal exam (DRE).
Results: 83 (32%) men had prostate cancer on biopsy of whom 45 (54%) had high grade disease (Gleason score 7
or higher). Our model had significantly higher accuracy than the base model in predicting cancer (area-under-the-
curve [AUC] improved from 0.63 to 0.78) or high-grade cancer (AUC increased from 0.77 to 0.87). Using a decision
rule to biopsy those with a 20% or higher risk of cancer from the model would reduce the number of biopsies by
nearly half. For every 1000 men with elevated PSA and clinical indication for biopsy, the model would recommend
against biopsy in 61 men with cancer, the majority (≈80%) of whom would have low stage and low grade disease
at diagnosis.
Conclusions: In this independent validation study, the model was highly predictive of prostate cancer in men for
whom the decision to biopsy is based on both elevated PSA and clinical work-up. Use of this model would reduce
a large number of biopsies while missing few cancers.
Background
Prostate specific antigen (PSA) is the only molecular
marker routinely used for the early detection of a com-
mon cancer. Data from the 2001 US Behavioral Risk
Factor Surveillance System are that 75% of men aged 50
years or older have had at least one PSA test and that,
of men aged 50 to 69 years - the ages typically targeted
in screening recommendations [1] - 54% reported
having had a PSA test within the past year [2]. These
numbers have remained fairly constant for data col-
lected in 2002, 2004, and 2006 [3]. Racial disparities in
PSA testing have been described. African-Americans
below 50 have higher rates of screening that younger
White men and Hispanic men [4,5], likely due to expli-
cit recommendations for an earlier start to screening in
this population [1]. Older African-Americans and Hispa-
nics have lower rates of screening than comparably aged
White men, an effect largely attributable to differences
in socio-economic status [3-5].
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The recent results of two large, randomized trials give
qualified support for the use of PSA screening. The
value of PSA testing in men who would otherwise not
be screened was assessed in the European Randomized
Study of Prostate Cancer (ERSPC). A total of 182,000
men in seven European countries were randomized to
PSA screening or control. The background rate of PSA
testing in these countries was low. At a median follow-
up of nine years, PSA screening was associated with a
statistically significant 20% relative reduction in the risk
of prostate cancer death. This difference is likely to
increase over time. However, this benefit came at high
cost, with an estimated 48 men needing to be treated
for prostate cancer in order to prevent one death, or
two cases of metastasis, at 9 years [6]. The US-based
PLCO trial, on the other hand, assessed a recommenda-
tion to screen in US men. As might be predicted from
the population-based surveys described above, many of
those accrued (~50%) had already had a PSA test. More-
over, many of the men randomized to the control group
continued to have PSA tests irrespective of randomized
assignment: 40% of men in the control group received a
PSA test in the first year after randomization. At a med-
ian follow-up of 7 years, prostate cancer specific mortal-
ity was very low, with no difference between arms [7].
PSA is an imperfect marker of prostate cancer.
Although highly specific to the prostate gland, PSA is
not specific for prostate cancer. We have previously esti-
mated that, each year, over 750,000 US men receive
unnecessary prostate biopsy [8].
There is clearly a need for better markers. We have
previously shown that a panel of four kallikrein markers
- total PSA, free PSA, intact PSA and human kallikrein-
related peptidase 2 (hK2) - is strongly predictive of
prostate biopsy outcome. In our initial report [8], we
calculated an area under the curve (AUC) of 0.83 for
the kallikrein panel, compare to just 0.68 for a “base”
model of total PSA and age alone. We reported that
using the full kallikrein panel would reduce biopsy rates
by more than 50% for men with elevated PSA while
missing only a small number of cancers (31 out of 152
low-grade and 3 out of 40 high-grade cancers).
We subsequently validated these results in several
independent cohorts of men. In the Rotterdam arm of
the ERSPC, we found that the panel resulted in a similar
improvement in predictive accuracy (AUC improved
from 0.64 to 0.76) and reduction of biopsy rates (573
per 1000 men with elevated PSA) while missing only a
small number of cancers (42 per 1000 men) [9]. These
results have also been replicated in previously screened
men [10,11].
In these prior studies, all men with an elevated PSA
were referred for biopsy as per the ERSPC protocol.
This is somewhat distinct to usual clinical practice in
which men with elevated PSA are typically subject to
clinical work-up before referral to biopsy. Clinical judg-
ment takes into consideration patient’s clinical history
to rule out transient prostatic inflammation, to assess
benign enlargement and evaluate prostate nodularity by
digital rectal examination (DRE). Recommendation for
biopsy might also take into consideration a range of
other factors, such as prostate symptoms, history of
benign prostate conditions, and family history of cancer.
It is known that this type of clinical work-up can affect
the properties of markers [12].
It is plausible that this type of clinical work-up and
judgment would affect the properties of predictive mod-
els for prostate cancer. Here we aim to determine
whether our previously created statistical model - devel-
oped on patients biopsied during the first round of the
ERPSC-Rotterdam where almost all men with elevated
PSA underwent biopsy - would retain its predictive
value in men biopsied in ERSPC France, where biopsy




During 2001-2005, 11,395 men were randomized to
receive screening as part of ERPSC-Tarn, France. Of
these, 4,200 men agreed to participate. These rates of
participation are lower than has been reported from
other ERSPC sites. This is likely because France entered
the study at a later time (2001 vs 1994 for the other
centers) and PSA was already relatively common in
France at that time, making subjects less likely to con-
sent to randomization [13]. According to the ERSPC
France protocol, the decision to biopsy was based on
clinical judgment following additional work-up such as
DRE or additional PSA test. If the repeat PSA was
below 3 ng/ml, or the DRE was not suspicious, the urol-
ogist could advise against biopsy [14].
Laboratory methods were as for our prior publications
[8,9]. Serum samples were retrieved from the archival
serum bank in Tarn (where they had been stored frozen
at -80°C after their initial processing within 3 hours
from venipuncture) and shipped frozen on dry ice to
Memorial Sloan-Kettering Cancer Center in 2008 for
the analysis of hK2. Samples were then shipped to the
Wallenberg Research Laboratories, Department of
Laboratory Medicine, Lund University, University Hos-
pital in Malmö, Sweden in 2009 for analysis of free,
total and intact PSA. Free and total PSA were measured
using the dual-label DELFIA Prostatus® total/free PSA
Assay (Perkin-Elmer, Turku, Finland). Intact PSA and
hK2 were measured by using F(ab’)2 fragments of the
monoclonal capture antibodies in order to significantly
reduce the frequency of non-specific assay interference.
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The intact PSA assay measures only free, uncomplexed
intact PSA (i.e. not cleaved at Lys145-Lys146). All ana-
lyses were conducted blind to biopsy result.
Statistical Methods
Our aim in this paper was to independently validate the
models built using participants of the Rotterdam arm of
the ERSPC. The development of these models has been
described previously [9]. In brief, we created a “base”
model using data routinely available in current clinical
practice (age, PSA, DRE) and a “full” model also incor-
porating levels of total PSA, free PSA, intact PSA and
hK2. In the original model, all markers were entered as
restricted cubic splines with knots at the tertiles to
allow a non-linear relationship with outcome. Multivari-
able logistic regression was used to fit all models.
We made several modifications to simplify our model
after completion of our research on the Rotterdam
cohort but before it was applied to the ERSPC Tarn
data. In brief, we eliminated non-linear terms for iPSA
and hK2 on the grounds that they substantially
increased model complexity yet, when evaluated on the
training set, did not markedly improve predictive accu-
racy. We have previously published an evaluation of the
use of this model on previously screened men [15].
Therefore the Tarn data was used for an entirely inde-
pendent replication of our prediction model.
We compared the value of the kallikrein models to a
base model of established predictors: age, total PSA and
DRE result. Predictive accuracy was reported as the area
under the receiver operating characteristics curve
(AUC). Confidence intervals and inference statistics for
differences between AUCs were obtained using the
method of Delong [16]. Confidence intervals for the dif-
ferences in AUC between models were calculated by
bootstrap methods. High grade cancer was defined as
Gleason grade 7 or higher. The AUC for high grade
cancer was calculated from the predicted probabilities of
any cancer, that is, we did not build a separate model
for the outcome of high grade disease. For these ana-
lyses, patients with low-grade cancer were classified the
same as patients with negative biopsy when high-grade
cancer was the outcome: five patients with missing
information on grade were considered to have low-
grade cancer.
To evaluate the clinical implications of these models,
we used decision curve analysis [17]. This method esti-
mates the “net benefit” of using a prediction model by
summing the benefits (true positives) and subtracting
the harms (false positives), where the latter is weighted
by a factor related to the relative harm of a missed can-
cer compared to an unnecessary biopsy. The weighting
is derived from the probability of prostate cancer at
which a patient would choose to be biopsied. As this
threshold probability can vary from patient to patient,
net benefit is calculated across a range of probabilities;
as in previous papers, we chose 10% - 40% as a reason-
able range. Five patients missing Gleason grade were
excluded from the analyses of high grade disease. Statis-
tical analyses were conducted using Stata 11.0 (Stata-
Corp LP, College Station TX).
Results
In total, 629 men had an elevated PSA (>= 3 ng/ml) in
round 1. Of these, 370 (59%) men received a biopsy.
Table 1 summarizes the additional workup (PSA test
and DRE) that men received, separately for those who
did and did not receive a biopsy. Overall, 489 (78%)
men received some form of further workup, either a sec-
ond PSA test (n = 123; 20%) or a DRE (n = 447; 71%).
Men who refused biopsy were more likely to have a sub-
sequent PSA test than those who received a biopsy (28%
vs 14%), but were less likely to have had an abnormal
DRE (44% vs. 90%).
Table 2 shows the characteristics of the sample. Men
who were not recommended for biopsy had slightly
lower PSA than those who were biopsied. For some
patients (n = 108) who underwent a biopsy, clinical data
or blood samples were not available. There were no
important differences between biopsied men with and
without marker data available: the cancer rate is 32% vs.
30% respectively, with 54% and 44% having high-grade
disease (i.e. Gleason ≥7 on biopsy). The majority of men
with complete data received an extended biopsy scheme;
45 (17%) received a biopsy with fewer than 10 cores.
The predictive accuracy of the model built on Rotter-
dam participants and applied to Tarn individuals is
shown in Table 3. The full-kallikrein panel had signifi-
cantly higher predictive accuracy than the base model
consisting of the established predictors of PSA, age and
DRE result alone: the AUC improved from 0.628 to
0.782 (improvement of 0.154; 95% CI: 0.086, 0.216).
Similar improvements were seen for the outcome of
high-grade cancer (Table 3).
To evaluate the individual contribution of each kallik-
rein, we fit a model to the initial Rotterdam training set
and evaluated it on the Tarn cohort, iteratively remov-
ing each marker. Free PSA appeared to have the largest
contribution but removing intact PSA and hK2 from the
model also led to a reduction in AUC. This supports
the use of all four kallikreins in the marker panel.
Table 4 illustrates the clinical implications of using the
kallikrein model to determine biopsy in men with ele-
vated PSA and considered eligible for biopsy after clini-
cal work-up. Using a threshold of 20% or greater risk
from the model as the indication for biopsy would lead
to a near halving of the biopsy rate. For every 1000 men
with elevated PSA and clinical indication for biopsy, 492
would avoid biopsy by use of the model; this would
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come at the expense of 61 men with cancer being
advised against biopsy. The majority of these cancers
would be low stage (all would be T1 or T2) and low
grade (only 12 would be Gleason 7 or higher).
To evaluate further the clinical implications of using
the four kallikrein panel, we created decision curves for
the outcome of any prostate cancer diagnosis (Figure 1).
The net benefit of the four kallikrein panel was superior
to the base model and a “biopsy all” strategy for all
threshold probabilities above 12%. Thus use of the panel
would be clinically beneficial for all but the most risk
averse men.
We have previously reported that the predictive accu-
racy of the full kallikrein panel is lower among men
with a history of PSA screening [10,11]. This finding is
largely due to the dramatically reduced predictive value
of PSA in these men. We planned a secondary analysis
stratifying by whether or not men reported a history of
PSA testing. Approximately half the men (n = 133; 51%)
reported a history of PSA testing. The results from the
stratified analysis confirmed both the main findings
reported here and our previous results that the accuracy
is reduced in previously screened men. Use of the kallik-
rein panel had greater discrimination that the base
Table 1 Details of further diagnostic workup of men with an elevated PSA
Men not undergoing subsequent biopsy N = 259 Men who received a biopsy N = 370
Repeat PSA 72 (28%) 51 (14%)
PSA 3.1 (2.4, 3.6) 4.6 (3.6, 7.2)
PSA < 3 ng/ml (% of those with second PSA) 34 (47%) 5 (10%)
Digital rectal exam 114 (44%) 333 (90%)
Abnormal findings (% of those with DRE) 16 (14%) 115 (35%)
Table 2 Patient characteristics
Men with an elevated PSA not
undergoing subsequent biopsy N = 259
Men who received a biopsy N = 370
Complete marker and DRE data N = 262 Missing marker or DRE N = 108




64 (59, 67) 63 (59, 67) 65 (61, 69) 65 (60, 67) 65 (61, 68)
Total PSA 3.75 (3.12, 4.80) N = 228 4.23 (3.36, 5.58) 4.86 (3.81, 7.23) - -
Free PSA 0.88 (0.67, 1.15) N = 228 1.01 (0.77, 1.32) 0.96 (0.67, 1.36) - -
Intact PSA 0.38 (0.27, 0.56) N = 228 0.45 (0.34, 0.63) 0.50 (0.33, 0.75) - -
Human
Kallikrein 2




- 12 (10, 12) 12 (10, 12) 11 (6, 12) 10 (6, 12)
Clinical T
Stage
T1 - - 31 (37%) - 13 (41%)
T2 - - 39 (47%) - 12 (38%)
T3 - - 8 (10%) - 1 (3%)




<= 6 - - 33 (40%) - 17 (53%)
7 - - 33 (40%) - 11 (34%)
>= 8 - - 12 (14%) - 3 (9%)
Missing - - 5 (6%) - 1 (3%)
All values are median (interquartile range) or frequency (proportion).
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model for both previously screened men (AUC 0.552 vs.
0.679) and those without a history of PSA screening
(0.692 vs. 0.865).
Discussion
We have replicated our previously published finding that
a panel of four kallikreins can predict the result of
biopsy for prostate cancer in men with elevated PSA.
Critically, we have shown that the model retains its
value in men who were clinically evaluated before an
extended biopsy. Use of the panel would dramatically
reduce biopsy rates while missing relatively few cancers,
most of which are low grade, limited stage prostate can-
cers typically thought to constitute overdiagnosis.
The aim of clinical work-up is to distinguish benign
from malignant causes of PSA elevation. For example, of
men with a second PSA lower than 3 ng/ml only a min-
ority (13%) went forward to biopsy; in comparison, 88%
of those with a positive DRE were biopsied. In total,
40% of men with elevated PSA were considered insuffi-
ciently high-risk after work-up to warrant biopsy. It is
plausible that aspects of benign and malignant prostate
disease captured by our panel would overlap with those
detected clinical work-up. As such, it seemed possible
that the four kallikrein panel’s contribution to risk-stra-
tification would be limited in the presence of clinical
judgment. Yet our findings indicate that the kallikrein
panel significantly improves prediction and would lead
to improved referral to biopsy, providing strong support
for the use of the full kallikrein panel in clinical practice.
Other promising markers of prostate cancer, such as
PCA3, have also been shown to enhance the
discrimination of prostate cancer on biopsy [18,19];
however, the improvements are smaller than those from
the full kallikrein panel. For example, Deras et. al.
reported that addition of PCA3 to a model including
prostate volume, DRE result and PSA improved the dis-
crimination of prostate cancer on biopsy from and AUC
of 0.67 to 0.75 [20]. In comparison, we show here that
use of the full kallikrein panel would increase the AUC
of prostate cancer from 0.63 to 0.78 over that of age,
PSA and DRE result alone.
A major strength of this paper is the close concor-
dance between our prior results and those reported
here. We found basing biopsy decisions on the kallikrein
panel would lead to 492 fewer biopsies per 1000 men
with an elevated PSA, but would miss 61 men with can-
cer of whom 12 had high-grade disease. The comparable
figures in the Rotterdam cohort were 513, 66 and 12. Of
note is the fact that the incidence of prostate cancer is
higher in Tarn than in Rotterdam (317 versus 277 can-
cers found per 1000 men with an elevated PSA) - clear
evidence that clinical judgment was able to select men
who were at higher risk of cancer. Yet despite the higher
incidence of prostate cancer in Tarn, use of the four kal-
likrein panel in this cohort did not lead to a greater
number of missed cancers.
There are several possible limitations of this study.
First, we do not know whether all men who refused
biopsy did not in fact have cancer. However, our study
is not subject to verification bias [21], as we only ana-
lyzed men who underwent biopsy. Indeed, we see it as a
positive advantage of our study that not all men with
elevated PSA underwent biopsy, as this reflects usual
clinical care. Second, the Tarn arm of the ERSPC had a
much lower rate of participation than the other arms of
the ERSPC and may not represent a population-based
cohort of men. Nonetheless, our prior studies evaluated
the kallikrein panel in representative population-based
cohorts and found consistent results to those reported
here.
Conclusions
We have independently replicated our prior finding that
a previously developed statistical model, based on four
kallikreins, is a strong predictor of biopsy outcome in
men with elevated PSA deemed eligible for biopsy after
clinical work-up. Using a decision analytic approach, we
Table 3 Predictive accuracy of models built on Rotterdam
participants when applied to Tarn participants
Clinical Model
Any cancer High grade cancer
Base model 0.628 (0.552, 0.704) 0.767 (0.687, 0.847)
Full kallikrein panel 0.782 (0.719, 0.845) 0.870 (0.807, 0.933)
without iPSA 0.753 (0.687, 0.818) 0.842 (0.776, 0.907)
without fPSA 0.688 (0.619, 0.758) 0.795 (0.721, 0.868)
without hK2 0.770 (0.706, 0.833) 0.853 (0.786, 0.919)
Cancers with pathologic Gleason score 7 or higher were considered high
grade. Base model includes age and total PSA (with splines) and DRE result.
Full model includes age, total PSA (with splines), free PSA (with splines), intact
PSA, hK2 and DRE result.
Table 4 Reduction in biopsies/cancers detected using as a threshold for biopsy a 20% or higher probability of cancer
No. biopsies No. cancers: No. high grade cancers:
Performed Avoided Found Missed Found Missed
Biopsy all men at risk 1000 0 (0%) 317 0 (0%) 175 0 (0%)
Biopsy if >= 20% risk from full model 508 492 (49%) 256 61 (19%) 163 12 (4%)
Numbers are given per 1000 men with elevated PSA (>= 3 ng/ml) and recommended for biopsy after clinical work-up.
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have also demonstrated that use of the model can
importantly reduce biopsy rates while delaying the diag-
nosis of only a limited number of cancers, the majority
of which are of low grade and low stage. This suggests
that use of the panel to determine biopsy in routine
clinical practice would improve decision making about
biopsy.
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